139 related articles for article (PubMed ID: 34144176)
41. Human papillomavirus vaccine.
Suba EJ; Raab SS;
N Engl J Med; 2007 Sep; 357(11):1155; author reply 1155-6. PubMed ID: 17874469
[No Abstract] [Full Text] [Related]
42. Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries.
Luciani S; Jauregui B; Kieny C; Andrus JK
Immunotherapy; 2009 Sep; 1(5):795-807. PubMed ID: 20636024
[TBL] [Abstract][Full Text] [Related]
43. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
44. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
45. HPV Vaccination in Bangladesh: Ethical Views.
Salwa M; Al-Munim TA
Recent Results Cancer Res; 2021; 218():31-37. PubMed ID: 34019160
[TBL] [Abstract][Full Text] [Related]
46. Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
Denny L; de Sanjose S; Mutebi M; Anderson BO; Kim J; Jeronimo J; Herrero R; Yeates K; Ginsburg O; Sankaranarayanan R
Lancet; 2017 Feb; 389(10071):861-870. PubMed ID: 27814963
[TBL] [Abstract][Full Text] [Related]
47. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates.
Jeudin P; Liveright E; Del Carmen MG; Perkins RB
Clin Ther; 2014 Jan; 36(1):24-37. PubMed ID: 24417783
[TBL] [Abstract][Full Text] [Related]
48. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
[TBL] [Abstract][Full Text] [Related]
49. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
50. No Vacillation on HPV Vaccination.
Sipp D; Frazer IH; Rasko JEJ
Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
[TBL] [Abstract][Full Text] [Related]
51. Modeling cervical cancer prevention in developed countries.
Kim JJ; Brisson M; Edmunds WJ; Goldie SJ
Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K76-86. PubMed ID: 18847560
[TBL] [Abstract][Full Text] [Related]
52. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer.
Vetter KM; Geller SE
J Womens Health (Larchmt); 2007 Nov; 16(9):1258-68. PubMed ID: 18001182
[TBL] [Abstract][Full Text] [Related]
53. Cervical cancer: the second-generation vaccines move forward.
Tuma RS
J Natl Cancer Inst; 2009 Jun; 101(11):774-5. PubMed ID: 19470948
[No Abstract] [Full Text] [Related]
54. Kosovo women's knowledge and awareness of human papillomavirus (HPV) infection, HPV vaccination, and its relation to cervical cancer.
Raçi PZ; Raçi F; Hadri T
BMC Womens Health; 2021 Oct; 21(1):354. PubMed ID: 34627223
[TBL] [Abstract][Full Text] [Related]
55. [Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].
Lazcano-Ponce E; Salmerón-Castro J; García-Carrancá A; Aranda-Flores C; Madrid-Marina V; Gómez-Altamirano CM; Martínez-Montañez OG
Salud Publica Mex; 2009; 51(4):336-41. PubMed ID: 19668929
[No Abstract] [Full Text] [Related]
56. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
[TBL] [Abstract][Full Text] [Related]
58. From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness.
Jit M; Prem K; Benard E; Brisson M
Prev Med; 2021 Mar; 144():106354. PubMed ID: 33309871
[TBL] [Abstract][Full Text] [Related]
59. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands.
Simons JJM; Vida N; Westra TA; Postma MJ
Vaccine; 2020 Jun; 38(30):4687-4694. PubMed ID: 32451211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
